April 24, 2026
5 min watch
In this video from the Macula Society meeting, Dilsher S. Dhoot, MD, FASRS, of California Retina Consultants, discusses 5-year data on pegcetacoplan for geographic atrophy secondary to age-related macular degeneration.
The results showed the long-term efficacy of continuous Syfovre (pegcetacoplan injection, Apellis) treatment in patients with GA and the benefits of earlier treatment vs. delayed treatment, according to a study abstract.
“We see [that] earlier treatment initiation preserved two times [the amount] of retinal tissue vs. delayed treatment,” Dhoot told Healio. “We see that pegcetacoplan treatment saved 1.5 years of disease progression.”
Dhoot also discussed the safety profile of pegcetacoplan.
Sources/Disclosures
Source:
Dhoot D, et al. Earlier treatment yields better outcomes: 5 years of pegcetacoplan treatment for geographic atrophy secondary to AMD. Presented at: Macula Society meeting; Feb. 25-28, 2026; Coronado, California.
Disclosures:
Dhoot reports consulting for Apellis Pharmaceuticals.
Ask a clinical question and tap into Healio AI’s knowledge base.
- PubMed, enrolling/recruiting trials, guidelines
- Clinical Guidance, Healio CME, FDA news
- Healio’s exclusive daily news coverage of clinical data
<
Leave a Reply